Alkermes, Inc.
$16.6M 83,613 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
GastroGPO, LLC
GastroGPO, LLC reported $16,628,947.80 across General Payments, Research, and Ownership to 8 physicians and teaching hospitals across 694 transactions.
- $16.6M Top 10% payer
- All-tracks total
- 694 Above-median volume
- Transactions
- 8 Below-median reach
- Recipients
- −$38.4K
- General Payments vs PY2023
GastroGPO, LLC reported $16,628,947.80 across all CMS Open Payments tracks (General + Research + Ownership) to 8 physicians and teaching hospitals in Program Year 2024 - ranking #112 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $3,683.00, averaging $2.1M per recipient.
How GastroGPO, LLC's $16.6M all-tracks total breaks down
GastroGPO, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
37/100
Total payments
A
100/100
Transaction volume
F
15/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer gastrogpo-llc GastroGPO, LLC
$16.6M · #112/1,925 · 0.1% industry · PY2024
- TOT $16.6M
- RANK #112
- SHARE 0.1%
- TXN 694
- RCP 8
- CAT 2
- GEN $3.7K
- ΔGEN −$38.4K
- TOP1 41.8%
- PY 2024
Volume peers
Nearest volume peer: Alkermes, Inc. ($16.6M)
GastroGPO, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
GastroGPO, LLC's CMS-reported General Payments decreased by $38.4K (−91.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: GASTROGPO, LLCPY2023: GASTROGPO, LLCPY2024: GastroGPO, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $42,066.00
- PY2024
- $3,683.00
What the Data Shows for GastroGPO, LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For GastroGPO, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 2 general-payment categories charted below, "Travel and Lodging" is the largest at $2.3K across 3 transactions, 63.4% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
GastroGPO, LLC made 2 types of general payments. "Travel and Lodging" is the largest category at $2.3K, 63.4% of General Payments.
How GastroGPO, LLC divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $2.3K | 3 | 63.4% |
| Food and Beverage | $1.3K | 5 | 36.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,683.00 (100.0%) of $3,683.00 in this company's General Payments records across 4 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for GastroGPO, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Paul Jerome Berggreen
$1,539.00 across 2 reported transactions
- 2
Timothy E Ritter
$1,406.00 across 3 reported transactions
- 3
Joseph Cappa
$659.00 across 2 reported transactions
- 4
Jonathon Casey Chapman
$79.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
GastroGPO, LLC ranks #112 of 1,925 by total payments (top 6% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #499 of 1,838 by HHI (top 27% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Acarix USA Inc. : $215.3K total payments, HHI 3569
- Natus Medical Incorporated : $59.5K total payments, HHI 3565
- Therakos Healthcare LLC : $35.7K total payments, HHI 3564
- CMF Medicon Surgical Inc. : $9.8K total payments, HHI 3560
- Fresenius Kabi USA, LLC : $1.3M total payments, HHI 3555
- Immunocore Limited : $1.1M total payments, HHI 3543
- GastroGPO, LLC (this company) : $3.7K total payments, HHI 3528
- Pfizer Chile S.a. : $16.9K total payments, HHI 3528
- Verathon Inc. : $672.8K total payments, HHI 3520
- J. Morita USA, Inc. : $88.2K total payments, HHI 3500
- DTE Oregon, Inc. : $304.57 total payments, HHI 3497
- Alcon Research LLC : $7.1M total payments, HHI 3482
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as GastroGPO, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about GastroGPO, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with GastroGPO, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Seqirus USA Inc
$16.7M 6,517 recipients
Compare payment profiles
Genmab U.S., Inc.
$16.5M 8,227 recipients
Compare payment profiles
Ipsen Biopharmaceuticals, Inc
$16.8M 20,198 recipients
Compare payment profiles
Vesalio, Inc.
$16.4M 18 recipients
Compare payment profiles
Aveo Pharmaceuticals, Inc.
$16.4M 4,805 recipients
Compare payment profiles
Put this to use
GastroGPO, LLC ranks #112 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See where GastroGPO, LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just GastroGPO, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.